Mineralocorticoid Receptor Antagonists
"Mineralocorticoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
| Descriptor ID |
D000451
|
| MeSH Number(s) |
D06.347.700 D27.505.696.399.450.600 D27.505.696.560.500.726.249
|
| Concept/Terms |
Mineralocorticoid Receptor Antagonists- Mineralocorticoid Receptor Antagonists
- Antagonists, Mineralocorticoid Receptor
- Receptor Antagonists, Mineralocorticoid
- Mineralocorticoid Antagonists
- Antagonists, Mineralocorticoid
- Aldosterone Receptor Antagonists
- Antagonists, Aldosterone Receptor
- Receptor Antagonists, Aldosterone
|
Below are MeSH descriptors whose meaning is more general than "Mineralocorticoid Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Mineralocorticoid Receptor Antagonists".
This graph shows the total number of publications written about "Mineralocorticoid Receptor Antagonists" by people in this website by year, and whether "Mineralocorticoid Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.
-
The need for potassium monitoring in women on spironolactone for dermatologic conditions. J Am Acad Dermatol. 2022 11; 87(5):1097-1099.
-
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Fail. 2021 04; 8(2):1130-1138.
-
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug; 110(8):1234-1248.
-
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.
-
Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
-
Hirsutism in Women. Am Fam Physician. 2019 08 01; 100(3):168-175.
-
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
-
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
-
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 07; 11(7):e004962.
-
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.